RxDoctor Payments Data

Christopher Karkut

Cardiovascular Disease · Greenville, NCNPI 1922208453

Payments from drug & device makers

$937in general payments, 2019–2025

Across 55 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Irhythm Technologies, Inc.$137
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$119
  • Novartis$100
  • E.r. Squibb & Sons, L.L.C.$97
  • Johnson & Johnson$92
  • Amgen$88
  • plus $303 from 8 others

What the payments were for

  • Food & beverage$90096%
  • Education$374%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$937 in reported general payments places this provider in the 30th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$226,312
Medicare patients
2,169
Services billed
3,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban412$343,637
EntrestoSacubitril/Valsartan48$63,865
XareltoRivaroxaban38$30,689
Repatha SureclickEvolocumab31$28,936
BrilintaTicagrelor26$22,733
Metoprolol Succinate424$4,167
Atorvastatin Calcium319$3,325
Isosorbide Mononitrate ErIsosorbide Mononitrate185$1,896
Ezetimibe115$1,871
Nebivolol Hcl33$1,664
Metoprolol Tartrate209$1,322
Ranolazine ErRanolazine12$1,313
Rosuvastatin Calcium136$1,099
Valsartan61$988
ClopidogrelClopidogrel Bisulfate87$951

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$343,637412 claims
NovartisEntresto$100$63,86548 claims
Johnson & JohnsonXarelto$92$30,68938 claims
AstraZenecaBrilinta$88$22,73326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →